Effects of Pioglitazone on Nonalcoholic Fatty Liver Disease in the Absence of Constitutive Androstane Receptor Expression

Figure 2

Hepatocyte fat accumulation after 12 weeks of pioglitazone treatment according to CAR activity. Representative hematoxylin and eosin staining of liver of mice. (a) CAR^+/+ control. (b) CAR^-/- control. (c) CAR^+/+ TCPOBOP. (d) CAR^+/+ with pioglitazone. (e) CAR^-/- with pioglitazone. (f) CAR^+/+ TCPOBOP with pioglitazone.

(a)

(b)

(c)

(d)

(e)

(f)